EMA recommends LFT for women on ulipristal for uterine fibroids
The European Medicines Agencys (EMAs) Pharmacovigilance Risk Assessment Committee (PRAC) recommended liver function testing at least monthly for women taking ulipristal acetate (Esmya, Gedeon Richter) for uterine fibroids due to reports of serious liver damage, requiring liver transplantation in some cases.
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies